Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin

@inproceedings{Yamamoto2008NextgenerationAF,
  title={Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin},
  author={Michiko Yamamoto and Akira Takakura and N. Masuda},
  booktitle={Drug design, development and therapy},
  year={2008}
}
Amrubicin is a totally synthetic anthracycline anticancer agent that acts as a potent topoisomerase II inhibitor. Amrubicin has been approved in Japan for the treatment of lung cancer, and the results from clinical studies of amrubicin as a single agent or as part of combination regimens for lung cancer, particularly for small cell lung cancer, conducted in Japan and overseas have been promising. Amrubicin should be included among new treatment strategies especially for chemoresistant patients… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
5 Citations
15 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 15 references

A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) taht is refractory or progressive within 90 days of completion

  • DS Ettinger, RM Jotte, V Gupta
  • 2008
3 Excerpts

A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensivedisease small-cell lung cancer (SCLC) sensitive to platinum-based fi rst-line chemotherapy

  • RM Jotte, PR Conkling, C Reynolds
  • Am Soc Clin Oncol Annual Meeting, Grunberg SM (ed…
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…